Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients

Phase 2

Active, not recruiting

• Conditions: Ulcerative Colitis
• Interventions: Drug: CBD, synthetic form; Drug: Placebo

• Registration Number: NCT06353828
• Lead Sponsor: CannaMore Biotechs

Brief Summary

Ulcerative proctitis can lead to considerable morbidity, and the available treatment options are limited. Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa, possesses potent immunomodulatory and anti-inflammatory properties as described in both acute and chronic animal models of inflammation, including IBD models.

Based on positive safety and initial efficacy profiles of CBD found in IBD animal and clinical studies, the main aim of this study is to evaluate the safety, tolerability and efficacy of a novel enema formulation of CBD for the treatment of active ulcerative proctitis.

Detailed Description

This study consists of 2 stages:

Stage 1. Feasibility - Open label stage:

Up to fourteen patients will be enrolled in this stage and receive a CBD enema formulation for 12 weeks treatment period.

If results of this stage prove to be safe and with clinical effect (reduction of 3 points in full Mayo score in at least 50% of patients), the study will proceed to stage 2.

Stage 2. Randomized, placebo controlled blinded stage:

Subjects will be randomized in a 2:1 ratio and receive the drug/placebo enema for a 12 weeks treatment period.

Patients will be assessed for full Mayo score on visit 1 and week 12, and partial Mayo score every visit. Patients will assessed by a clinician using the self reported outcome (PRO) scale every visit. Sigmoidoscopy will be performed at baseline and week 12.

Study Timeline

• Study Start: 2023-03-01
• Status Verified: 2024-03
• Study First Submitted: 2024-03-28
• Primary Completion: 2024-04-01
• Study First Submitted QC: 2024-04-04
• Last Update Submitted: 2024-04-04
• Study First Posted: 2024-04-09
• Last Update Posted: 2024-04-09
• Study Completion: 2025-04-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

1. Age ≥18 years
2. Diagnosis of UC at least 3 months prior to the Screening Visit
3. Patients who were not treated rectally for UC in the last 3 days.
4. UC patients with active disease and being treated with stable doses of biologics (at least 2 months), and/or steroids (at least 1 months) and/or oral mesalazine (at least 2 months at stable dose (4 gr)) or non-treated patients)
5. Full Mayo score ≥4 to < 9 (range: 0-12) prior to enrolment in the study
6. Patients that did not respond to Mesalamine treatment.
7. Non-pregnant (via negative pregnancy test)/non-breast-feeding women and women with no intention to become pregnant/to breast-feed during the term of the trial and for at least one month after cessation of IcBD-01 treatment
8. Male subject with female partner(s) of child-bearing potential (including breastfeeding partner[s]) must agree to use contraception throughout the treatment period and for one month after final IMP administration.
9. Subject able to provide written informed consent
10. Must be able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria

1. Diagnosis of severe extensive pancolitis
2. Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis, or diverticular disease-associated colitis
3. Complete resection of the colon with the need of a pouch
4. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections (including but not limited to tuberculosis, atypical mycobacterial disease, and herpes zoster), human immunodeficiency virus (HIV), or any major episode of infection requiring hospitalization or treatment with intravenous (IV) or oral antibiotics within 4 weeks of screening
5. Sexual transmitted diseases
6. Using rectal formulations (such as Mesalazine) for the last 3 days
7. Subjects who have received any investigational drug or used investigational device in the last 2 months
8. Serious psychiatric or psychological disorders
9. Active consumption of illicit drugs including cannabis or derivatives for at least 1 months prior to the study
10. Patients with short bowel syndrome, symptomatic stricture, abscess, recent history (within the previous 3 months) of abdominal surgery
11. Patients with significant cardiac, hepatic, respiratory disease comorbidities or active malignancy
12. Renal comorbidity: eGFR< 30 mL/min/1.73 m2 (note: CKD Grade 4 is defined as eGFR 15-29 mL/min/1.73 m2)
13. Patient who is taking immunomodulatory medications for other indication(s)
14. Women of child-bearing potential who intend to become pregnant or who are pregnant or breastfeeding or male subjects with female partners who intend to get pregnant or breastfeed during the trial period

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
IcBD-01	CBD, synthetic form	IcBD-01 is a novel Cannabidiol enema formulation
placebo	Placebo	placebo enema formulation

Primary Outcome Measures

Name	Time	Method
Change from baseline in Full Mayo Score	12 weeks	The Mayo Score is used to assess the severity of ulcerative colitis and can range from 0-12, with higher scores indicating worse severity.

Secondary Outcome Measures

Name	Time	Method
Change in Partial Mayo Score	12 weeks	The partial Mayo Score is used to assess the severity of UC and does not include the endoscopic parameter. Can range from 0-9, with higher scores indicating worse severity.
Change in patient reported outcome (PRO-UC)	12 weeks	PRO-UC Diary is a tool to quantify the patient perspective in terms of how they feel and function. Can range from 0-20, with higher scores indicating worse severity
Change in the length of the inflamed colon	12 weeks	Length of inflamed colon (Mayo subscore) will be measured through endoscopy
Change in endoscopic Mayo subscore in distal 15 cm of anus	12 weeks	Efficacy will be determined through the use of the Mayo Endoscopic Subscore.

Trial Locations

Locations (1)

Meir Medical Center; 🇮🇱 Kfar Saba, Israel